Estimated read time: Less than a minute
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
SALT LAKE CITY -- Utah will receive $500,000 as part of a pharmaceutical company settlement.
Attorney General Mark Shurtleff announced that Utah will get a portion of the $750 million settlement with GlaxoSmithKline over allegations the pharmaceutical company sold adulterated drugs.
The whistleblower's complaint alleged GSK knowingly manufactured, distributed and sold four products --Paxil CR, Avandamet, Kytril and Bactroban -- whose strength, purity and/or quality fell below the standards required by the FDA:
- Paxil CR: A controlled-release antidepressant that included split tablets, causing recipients to receive either product with no active ingredient and/or product with only the active ingredient layer and no controlled release mechanism.
- Avandamet: A diabetes medication with tablets containing higher or lower amounts of the active ingredient than specified.
- Kytril: An anti-nausea drug labeled as sterile but with some vials containing impurities.
- Bactroban: Antibiotic ointments and creams that, in some packages, were contaminated with microorganisms.
